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Platelet transfusion can elicit alloimmune responses leading to alloantibody formation against 
donor-specific polymorphic residues, ultimately resulting in platelet transfusion refractori-
ness. Universal leukoreduction significantly reduced the frequency of alloimmunization after 
platelet transfusion, thereby showing the importance of white blood cells (WBCs) in inducing 
this alloresponse. It is, however, unknown if the residual risk for alloimmunization is caused 
by WBCs remaining after leukoreduction or if alloimmunization can be induced by platelets 
themselves. This study investigated the capacity of platelets to induce allo immunization 
and identified potential product-related risk factors for alloimmunization. First, internalization 
of allogeneic platelets by dendritic cells (DCs) was demonstrated by confocal microscopy. 
Second, after internalization, presentation of platelet-derived peptides was shown by mass 
spectrometry analysis of human leukocytes antigen (HLA)-DR eluted peptides. Third, plate-
let-loaded DCs induced platelet-specific CD4 T cell responses. Altogether, this indicates 
a platelet-specific ability to induce alloimmunization. Therefore, factors enhancing platelet 
internalization may be identified as risk factor for alloimmunization by platelet concentrates. 
To investigate if storage of platelets is such a risk factor, internalization of stored platelets 
was compared with fresh platelets and showed enhanced internalization of stored plate-
lets. Storage-induced apoptosis and accompanied phosphatidylserine exposure seemed 
to be instrumental for this. Indeed, DCs pre-incubated with apoptotic platelets induced the 
strongest IFN-γ production by CD4 T cells compared with pre-incubation with untreated 
or activated platelets. In conclusion, this study shows the capacity of platelets to induce 
platelet-specific alloimmune responses. Furthermore, storage-induced apoptosis of plate-
lets is identified as potential risk factor for alloimmunization after platelet transfusions.
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inTrODUcTiOn
The effectiveness of prophylactic platelet transfusions can be monitored by determining the increase 
in circulating platelets after transfusion (the count increments), prevention of bleeding and/or the 
time to the next transfusion. If patients display multiple subsequent ineffective transfusions they 
are considered to be refractory for platelet transfusion. This is a frequent clinical problem, which 
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is observed in 7–37% of hemato-oncological patients receiv-
ing multiple platelet transfusions (1–3). Platelet refractoriness 
is associated with prolonged hospital stay, increased risk for 
bleeding and reduced survival (3, 4). Next to non-immune 
factors, immune-mediated refractoriness to platelet transfusions 
occurs in 5–15% of all patients receiving platelets transfusions 
(2, 5, 6). This is most frequently caused by alloimmunization of the 
recipient against non-matching human platelet antigens (HPA) 
or human leukocytes antigens (HLA) class I that are recognized 
as foreign by the recipient (6, 7). The resulting alloantibodies 
can induce platelet transfusion refractoriness, especially when 
targeting HLA class I antigens (6). Besides causing refractori-
ness, HLA class I alloimmunization complicates curative stem 
cell therapies (2).
Although alloimmunization after platelet transfusions 
is suggested to be initiated via either the direct or indirect 
pathway of allorecognition (6), the indirect pathway seems 
to be dominant for humoral alloimmunization (1, 8). IgG 
alloimmunization via the indirect pathway is initiated when 
antigen-presenting cells are stimulated by nitric oxide to pro-
cess and present allogeneic antigens (8–10). These presented 
allopeptide–MHC complexes must be recognized by CD4 
T cells (11), to subsequently provide help to alloreactive B cells 
as necessary step in the eventual production of alloantibodies. 
Directed against transfused platelets, such alloantibodies result 
in rapid clearance of antibody opsonized platelets, rendering 
subsequent transfusions more and more ineffective (12, 13). It 
is known that previous sensitization (e.g., by pregnancy) and 
repeated exposures to platelet concentrates increase the risk 
for alloimmunization (2, 6), but knowledge regarding patient 
and product-related risk factors for alloimmunization remains 
very limited.
Most interesting in this respect is that even though platelets 
are most abundant, the contaminating white blood cells (WBCs) 
in platelet concentrates (PCs) are so far held mainly responsible 
for the induction of alloimmunization (2, 6, 14–16). Indeed, in 
early days, alloimmunization after platelet transfusion seemed 
completely prevented when PCs were depleted from contami-
nating WBCs (17–19). These findings led to the proposal that 
platelets themselves are incapable of inducing alloimmunization 
(17, 18, 20). By contrast, more recent animal studies suggest 
that platelets themselves are capable of inducing alloimmune 
responses against HLA class I (8–10); however, residual WBCs 
were still present in platelet products making it impossible to dis-
sect the role of platelets and WBCs in the observed alloimmune 
responses. Although universal leukoreduction significantly 
reduced alloimmunization after platelet transfusions in vivo (1, 
2), alloimmunization still occurs and it is unknown whether this 
is caused by WBCs still contaminating platelet concentrates or 
also by platelets themselves.
Alloantibodies induced by platelet transfusions are most 
frequently directed against HLA class I (15, 21), but platelets 
additionally express various molecules with polymorphisms, 
known as HPAs, against which alloantibodies can also be 
formed. Currently, 33 HPAs are described which are expressed 
on 6 different glycoproteins (22, 23). Expression of HPAs, 
however, is not limited to platelets, as for example HPA-5 and 
-13 are in glycoprotein Ia/CD49b, which can also be expressed 
by T, B, and NK cells (24, 25). Furthermore, the expression of 
glycoprotein IIIa/CD61, which contains seven HPAs, is also 
reported for endothelial cells, trophoblasts, and osteoclasts 
(23, 26–28). Therefore, although immunization against HPA 
suggests that platelets themselves can induce alloimmunization, 
this may be mediated by other cells.
This study investigates the capacity of platelets to induce 
alloimmune responses and identifies potential product-related 
risk factors for alloimmunization after platelet transfusion. In 
this respect, we show internalization of allogeneic platelets by 
dendritic cells (DCs), which is significantly enhanced after stor-
age. This internalization results in presentation of platelet-derived 




Leukapheresis products or whole blood derived buffy coats 
obtained from anonymized Sanquin blood donors after giving 
written informed consent were used to isolate monocytes from 
random or HLA-DRB3*01:01-positive individuals. Citrated 
whole blood was obtained to isolate HPA-1a+, HPA-1a−, or 
fresh platelets. Full blood donations from anonymized Sanquin 
blood donors were used to prepare platelet concentrates. All was 
approved by the Sanquin Ethical Advisory Board and in accord-
ance with the declaration of Helsinki and according to Dutch 
regulations.
Platelet concentrates
Buffy coats were obtained from full blood donations as previously 
described (29). Platelet concentrates (PCs) were prepared from 
five pooled buffy coats, and 1 U of plasma obtained from one of 
these donors. After pooling and 4.5 min centrifugation at 1,940 g, 
platelet-rich plasma was transferred via a leukoreduction filter to 
a storage container using an automated separator (Compomat, 
Fresenius, Emmer Compascuum, The Netherlands). Products 
were left either untreated (control) or were treated with Mirasol 
pathogen reduction technology (TerumoBCT, Zaventem, 
Belgium). Mirasol-treated products were always produced in par-
allel with a paired untreated unit, and therefore two ABO-identical 
platelet concentrates were pooled, mixed, and subsequently split 
to allow a paired comparison. Mirasol treatment was performed 
according to the manufacturer’s instructions. In short, 50  mM 
riboflavin was added to PCs, which were subsequently UV-B 
illuminated for 5–10 min with 6.2 J/ml. All products were stored 
at room temperature with gentle agitation, up to a maximum of 
15 days [7 days is the current standard in the Netherlands, but we 
also wanted to investigate more exceptional cases and transfused 
platelets remain in circulation up to 15 days after collection (30)]. 
All PCs were tested negative for bacterial contamination using 
BactAlert (bioMérieux, Marcy-l’Étoile, France) and fulfilled 
standard quality requirements (i.e., <1 × 106 leukocytes/product, 
visible swirl “not red,” >250 × 109 platelet/product, 150–400 ml 
total volume).
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Platelet Preparations and Membrane 
labeling
Platelet rich plasma was obtained by centrifugation of freshly 
drawn citrated blood from healthy individuals at 200 g for 10 min 
or by taking 10 ml samples from PCs on day 1, day 7, and/or day 15 
of storage. Subsequently, platelets were washed, and if indicated, 
labeled 20  min in PBS using 3.75  µM PKH26 cell membrane 
dye (Sigma Aldrich, Zwijndrecht, The Netherlands) under con-
tinuous gentle agitation, after which platelets were washed once 
using sequestrine buffer [17.5 mM Na2HPO4, 8.9 mM Na2EDTA, 
154 mM NaCl, pH 6.9, containing 0.1% (wt/vol) bovine serum 
albumin, all obtained from Merck Millipore, Amsterdam, The 
Netherlands] supplemented with 10% heat inactivated fetal calf 
serum (Bodinco, Alkmaar, The Netherlands). If indicated, plate-
lets were left untreated, activated using 100 µM thrombin recep-
tor activator peptide 6 amide (Bachem, Bubendorf, Switzerland), 
made apoptotic using 5 µM Calimycin A23187 (Sigma Aldrich) as 
previously described (31, 32). Alternatively, platelets were incu-
bated with either 250 µg/ml purified bovine phosphatidylserine 
(PS) or phosphatidylcholine (both from Sigma Aldrich), which 
was shown to result in incorporation in the outer membrane of 
RBCs (33). After 20 min, platelets were washed using sequestrine 
buffer, centrifuged at 1,600 g for 5 min and dissolved in Cellgro 
DC serum-free medium (Cellgenix, Freiburg, Germany). To 
determine the effects of pathogen reduction, activation or 
apoptosis induction and exposure to purified PS or phosphati-
dylcholine, 0.5  ×  106 platelets were stained either in PBS with 
phycoerythrin-cyanine 7-labeled anti-CD61 (Beckman Coulter, 
Woerden, The Netherlands) combined with either fluorescein 
isothiocyanate (FITC)-labeled anti-CD62P (Beckman Coulter) 
or phycoerythrin-cyanine 5-labeled anti-HLA class I (clone 
W6-32, BioLegend, London, UK) or in annexin V binding buffer 
(BioLegend) with allophycocyanin (APC)-labeled Annexin V 
(BD Biosciences, Breda, The Netherlands).
human Dcs
Monocytes were isolated either from fresh leukapheresis material 
using the Elutra Cell Separation System (Gambro, Lakewood, 
CO, USA) or from HLA-typed buffy coats using Ficoll density 
centrifugation and CD14 microbead MACS isolation (Miltenyi, 
Leiden, The Netherlands) as previously described (34, 35), and 
subsequently frozen until further use. Purity of monocytes was 
determined using flow cytometry with APC-labeled anti-CD14, 
PE-labeled anti-CD3, and FITC-labeled anti-CD66b (all from BD 
Biosciences) and was >90%. On day 0, monocytes were thawed 
and differentiated into DCs by culturing 1 × 106 monocytes/ml 
in a T75 culture flask or 6-well plate (both from Nunc/Sanbio BV, 
Uden, The Netherlands) in 20 or 2 ml of Cellgro DC serum-free 
medium (Cellgenix), respectively, supplemented with 800 IU/ml 
IL4 and 1,000 IU/ml granulocyte–macrophage CSF (both from 
Cellgenix, Freiburg, Germany), 100 U/ml penicillin, and 100 U/ml 
streptomycin (both from Gibco/Thermo Fischer Scientific, The 
Netherlands) at 37°C and 5% CO2 for 6–7 days.
Platelet internalization by Dcs
DCs were harvested and incubated 0.5–4 h in 1:5–1:80 ratio with 
PKH-labeled platelets at 37°C and 5% CO2. After incubation, 
DCs used for confocal microscopy were washed with PBS + 0.5% 
BSA and fixed with 3.7% paraformaldehyde (Sigma Aldrich). 
Subsequently, DCs were quenched with 50  mM NH4Cl and 
labeled for 30  min with unlabeled rabbit antihuman HLA-DR 
(Abcam, Cambridge, UK) in PBS with 3 mg/ml human gamma 
globulin. After washing, DCs were incubated 45  min with 
Alexa 647-labeled anti-rabbit Ig (ThermoFisher, Bleiswijk, The 
Netherlands) supplemented with 1  µg/ml DAPI nuclear coun-
terstain (Life Technologies). Subsequently cells were washed, 
taken up in 10 µl Mowiol mounting medium (Calbiochem, EMD 
Millipore, Billerica, MA, USA) and put on a cover slip after which 
samples were analyzed using confocal microscopy (LSM 510 
META, Zeiss, Breda, The Netherlands). Alternatively, DCs used 
for image stream analysis were washed with PBS + 0.5% BSA supple-
mented with 5 mM EDTA (Merck Millipore) to release surface 
bound platelets after which they were fixed with 3.7% paraform-
aldehyde (Sigma Aldrich). Subsequently, DCs were incubated 
at RT with FITC-labeled anti-CD61 (Beckman Coulter) and 
APC-labeled anti-HLA-DR (both from BD Biosciences, Breda, 
The Netherlands). After 30 min, cells were washed and analyzed 
using imaging flow cytometry (ImageStream®X Mark II Imaging 
Flow Cytometer, Merck Millipore) and IDEAS Application 
(IDEAS software V6.1.303.0, Merck Millipore). Gating strategy 
is presented in Figure S1 in Supplementary Material, and involved 
selection of single DCs (aspect ratio intensity vs area; for bright 
field and APC/BV650 channel), DCs and platelets in focus 
(gradient RMS; for bright field, APC/BV650 channel and PKH 
channel), and exclusion of false positive cells (defined as intracel-
lular fluorescence of the platelet-specific anti-CD61 membrane 
staining).
antigen Presentation
The presentation of platelet-derived peptides was performed 
as previously described (36). In short, 5 × 106 DCs were incu-
bated in a 1:40 ratio with freshly isolated platelets at 37°C and 
5% CO2. After 5  h of incubation, DCs were matured for 19  h 
with 1  µg/ml lipopolysaccharide (LPS, Sigma Aldrich) and 1% 
FCS. Subsequently, the DCs were collected and resuspended 
in lysis buffer [10  mM Tris (Merck Millipore), 0.25% octyl-b-
d-glucopyranoside, 1% sodium deoxycholate and protease/
phosphatase inhibitor cocktail (all three from ThermoFisher)]. 
Lysates were then clarified by centrifugation at 20,000  g for 
15 min at 4°C, and the supernatants were incubated with 300 µl 
of Sepharose beads coupled with anti-HLA-DR antibody L243 to 
immunoprecipitate HLA-DR/peptide complexes. After overnight 
incubation, samples were washed twice with fresh lysis buffer 
and five times in 10  mM Tris. Bound HLA-DR/peptides were 
eluted from the beads using 10% acetic acid (Sigma Aldrich) 
and desalted using C18 STAGE-Tips (3M Science) before mass 
spectrometry analysis.
Mass spectrometry Data acquisition
Peptides were separated by nanoscale C18 reverse phase chro-
matography coupled on line to an LTQ Orbitrap XL mass spec-
trometer (Thermo Scientific) via a nanoelectrospray ion source 
(Nanospray Flex Ion Source, Thermo Scientific). Peptides were 
loaded on a 20 cm 75–360 µm inner–outer diameter fused silica 
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emitter (New Objective) packed in-house with ReproSil-Pur 
C18-AQ, 1.9  µm resin (Dr. Maisch GmbH). The column was 
installed on a Dionex Ultimate 3000 RSLC nanoSystem (Thermo 
Scientific) using a MicroTee union formatted for 360 µm outer 
diameter columns (IDEX) and a liquid junction. The spray volt-
age was set to 2.15 kV. Buffer A was composed of 0.5% acetic 
acid in water and buffer B of 0.5% acetic acid, 19.5% water, 80% 
acetonitrile (Biosolve Valkenswaard, The Netherlands). Peptides 
were loaded at 300 nl/min at 4% buffer B, equilibrated for 10 min 
at 4% buffer B (0–10  min), and eluted by increasing buffer B 
from 4 to 50% (10–50 min), followed by a 3 min wash to 90%, 
2  min hold at 90%, a 2  min ramp back to 4%, and a 13  min 
regeneration at 4%.
Survey scans of peptide precursors from 300 to 2,000 m/z were 
performed in the Orbitrap at 30K resolution. Tandem mass spec-
trometry of the five most intense precursors was performed by 
isolation with isolation width 1.0, CID fragmentation with nor-
malized collision energy of 35, and rapid scan mass spectrom-
etry analysis in the ion trap. The dynamic exclusion duration was 
set to 30 s with a 10 ppm tolerance around the selected precursor 
and its isotopes. Monoisotopic precursor selection was turned on. 
The MS2 ion count target was set to 500, and the max injection 
time was 30 ms. Only those precursors with charge state 2 and 
up were sampled for MS2. All data were acquired with Xcalibur 
software. Data files were analyzed with Proteome Discoverer 
software, version 1.4 (Thermo Scientific) against a human 
FASTA database (uniProt organism 9606 + keyword 0181) with 
a 20 ppm tolerance for precursor mass and 10 ppm tolerance for 
fragment mass. Modifications used were static carbamidomethyl 
(+57.021 Da) on cysteines and dynamic oxidation (+15.995 Da) 
on methionine. Only peptides with a high confidence (FDR 
threshold 0.05%) were considered for protein scoring.
human Platelet antigen 1a (hPa-1a)-
specific T cell responses
To investigate if antigen uptake by DCs resulted in immune 
responses, 5 ×  103 HLA-DRB3*01:01 DCs were first incubated 
4  h in 1:100 ratio with freshly isolated platelets (untreated, 
activated and/or apoptotic) in Cellgro DC serum-free medium 
(Cellgenix) at 37°C and 5% CO2. If indicated, DCs were harvested 
and washed twice at 300 g using IMDM culture medium (Lonza, 
Breda, The Netherlands) supplemented with 5% pooled human 
serum, 5% fetal calf serum (Bodinco, Alkmaar, The Netherlands), 
IgG-depleted transferrin, 2-mercaptoethanol (βME), 100  U/ml 
penicillin, and 100 U/ml streptomycin (both from Gibco/Thermo 
Fischer Scientific, The Netherlands), and replated in a 96-well flat 
bottom plate. Next, CD4 T cells specific for HPA-1a presented 
in HLA-DRB3*01:01 [clone D8T108, for isolation and expansion 
see Ref. (37)] were added in a T:DC ratio of 10:1 in the presence 
of 500 ng/ml LPS (Invivogen, San Diego, CA, USA). After over-
night incubation, culture supernatant was harvested, and IFN-γ 
production was determined using ELISA (Sanquin Reagents, 
Amsterdam, Netherlands).
statistical analysis
Graphical presentation and statistical analyses was performed 
with GraphPad prism v7.02 (GraphPad Software Inc., La Jolla, 
CA, USA). A repeated measures one-way ANOVA with Tukey 
posttesting was used to determine statistical differences induced 
by pathogen reduction in internalization of platelets by DCs, 
platelet HLA class I expression, activation and apoptosis. 
Differences in internalization of stored vs fresh platelets were 
investigated using a paired T-test. Furthermore, statistical dif-
ferences in internalization of apoptotic vs activated platelets or 
PS- vs phosphatidylcholine-treated platelets and in all reported 
CD4 T-cell responses were investigated using a repeated meas-
ures one-way ANOVA with Tukey posttesting.
resUlTs
Platelet internalization and Presentation  
in hla class ii by Dcs
The first step required for alloimmunization after platelet 
transfusion is internalization of platelets by antigen-presenting 
cells. Platelet internalization by DCs was investigated after 4  h 
incubation using confocal microscopy. z-Stacks were obtained 
and visualized using orthogonal representation (Figures 1A,B). 
These images show that DCs are capable of internalizating plate-
lets. Subsequently, platelet internalization by DCs was quantified 
with imaging flow cytometry and an optimized internalization 
assay (Figure S1 in Supplementary Material). In time, more DCs 
internalized platelets (Figure 1C) and each DC internalized more 
platelets (Figure 1D). In addition, increasing platelet:DC ratio also 
increased platelet internalization (Figure S2 in Supplementary 
Material).
Antigen processing and presentation on HLA class II mol-
ecules is a second pivotal step to initiate CD4 T cell-mediated 
alloimmune responses. To investigate if internalized platelets 
were also processed and presented by DCs in HLA class II 
molecules, HLA-DR from DCs was immunoprecipitated after 
incubation with platelets and bound peptides were subsequently 
analyzed using mass spectrometry. The most abundantly pre-
sented peptides were derived from general household proteins, 
as previously shown (38). To exclude endogenous peptides 
presented by DCs, all peptides presented by DCs incubated 
without platelets were removed from the results. After this, 
207 and 547 unique presented peptides were identified in two 
separate experiments, in which we focused on peptides derived 
from platelet-specific proteins to establish if presentation of 
platelet-derived peptides occurred. Of note, because HLA class 
I is expressed by all cells, including DCs, it was not possible 
to investigate presentation of HLA class I derived peptides. 
However, peptides from the platelet-specific glycoprotein V 
were found in each of two independent experiments (Table 1). 
These peptides were not detected in any of the medium controls, 
neither by automatic nor by manual inspection of mass spectra. 
Glycoprotein V was the only platelet-specific protein that was 
consistently identified, presumably due to limited sensitivity 
of this assay. The identified glycoprotein V-derived peptides 
exhibited similar core amino acids between both donors while 
the flanking regions of these peptides were variable. This is 
strongly indicative of intracellular antigen processing before 
their presentation.
TaBle 1 | HLA class II presentation of platelet-derived peptides by DCs.





FigUre 1 | Allogeneic platelets are internalized by dendritic cells (DCs). DCs were incubated 1:40 with PKH-labeled platelets (green). After 4 h incubation, DCs 
were stained with HLA-DR (red) and DAPI nuclear counterstain (blue) and measured with confocal microscopy (LSM 510 META, Zeiss). To allow visualization from 
every axis, z-stacks (5–10 slices of 1 μm/slice) were obtained and visualized with an orthogonal presentation (a,B). In addition, using imaging flow cytometry platelet 
internalization by DCs over time was quantified by determining % of DCs with platelets internalized (c) and the intracellular PKH fluorescence in DCs that 
internalized platelets (D) (n = 6). One-way ANOVA with Tukey posttesting was used to determine statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and 
****p < 0.0001).
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Platelet-specific T cell responses
Because IgG alloantibody production by B  cells requires help 
from activated CD4 T  cells, the potential of DCs to activate 
platelet-specific CD4 T  cells was investigated after incubation 
of DCs with platelets. To exclude activation of CD4 T  cells by 
antigens derived from a non-platelet source, e.g., contaminating 
WBCs, T cells recognizing HPA-1a peptides presented in HLA-
DRB3 were used. HPA-1a is a minor histocompatibility antigen 
(22, 23), whose expression in all circulating cells is only reported 
for platelets (22, 27, 28, 39). Platelet-loaded DCs matched for 
HLA class II were incubated with the CD4 T cell clone. DCs that 
were incubated with platelets obtained from HPA-1a positive 
individuals induced significant IFN-γ production by the HPA-1a-
specific CD4 T cells, which increased when more platelets were 
present (Figure  2A). However, this IFN-γ production was not 
induced when only platelets were added to the T cells. Although 
some IFN-γ production was induced when only DCs were added 
to CD4 T cells, this was similar when DCs were exposed to plate-
lets from HPA-1a negative (thus HPA-1b homozygous) donors 
(Figure 2B). This demonstrates that DCs internalize platelets and 
subsequently present platelet-derived peptides in HLA class II to 
platelet-specific CD4 T cells.
Product-related Factors causing 
increased internalization of Platelets
With the evidence above showing the ability of platelet-derived 
antigens to induce CD4 T cell responses, product-related factors 
like storage and pathogen reduction could be envisioned as risk 
factors for platelet dependent alloimmunization, as they may 
affect platelet internalization and subsequent presentation of 
FigUre 3 | Internalization of allogeneic platelets by dendritic cells (DCs) increases upon storage. Platelets were stored 7 days in platelet concentrates (PCs) under 
blood bank conditions [(a); n = 6]. Alternatively, paired PCs were prepared with or without pathogen reduction and stored for 1, 4, 7, or 15 days [(B); n = 4]. 
Subsequently, stored platelets were incubated 2 h 40:1 with DCs, and internalization of platelets was determined using imaging flow cytometry. In addition, platelet 
activation [(c), n = 3] and apoptosis [(D), n = 3] were determined using flow cytometry. Statistical analysis was performed using unpaired T-test (a) or one-way 
ANOVA with Tukey posttesting (B–D) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
FigUre 2 | Presentation of platelet-derived peptides by dendritic cells (DCs) induces a CD4 T cell response. Human platelet antigen 1a (HPA-1a)-specific CD4 
T cells were incubated with DCs that were pre-incubated 4 h with different PLT:DC ratio with HPA-1a positive platelets [(a), PLT:DC ratio 100:1 and 10:1, n = 3] or 
with either no platelets, HPA-1a negative (i.e., HPA-1b) or positive platelets [(B), PLT:DC ratio 100:1, n = 4] after which the HPA-1a-specific T cells were added. After 
overnight incubation, IFN-γ production by T cells was determined using ELISA. One-way ANOVA with Tukey posttesting was used to determine statistical 
significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
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platelet-derived antigens in HLA class II. Therefore, internali-
zation of stored platelets with or without pathogen reduction 
by DCs was quantified. Internalization of platelets stored for 
7 days under routine blood bank conditions was significantly 
enhanced compared with freshly isolated platelets (Figure 3A). 
Directly after treatment, pathogen reduction by Mirasol did not 
result in increased internalization of platelets compared with 
untreated platelets. Upon storage, however, internalization of 
pathogen-reduced platelets was significantly enhanced com-
pared with similarly stored control PCs (Figure 3B).
FigUre 4 | Apoptosis and phosphatidylserine (PS) exposure increase internalization of platelets by dendritic cells (DCs). Freshly isolated platelets were activated, 
made apoptotic or left untreated [(a), n = 6]. Alternatively, platelets were incubated with 250 µg/ml PS or phosphatidylcholine (PC) [(B), n = 4]. Subsequently, these 
platelets were incubated 2 h 40:1 with DCs, and internalization of platelets was determined using imaging flow cytometry. Statistical analysis was performed using 
one-way ANOVA with Tukey posttesting (**p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not significant).
FigUre 5 | Dendritic cells (DCs) primed with apoptotic platelets induce 
enhanced CD4 T cell response. DCs were incubated with apoptotic, 
activated or untreated freshly isolated platelets, washed after 4 h, and 
subsequently incubated with human platelet antigen 1a (HPA-1a)-specific 
CD4 T cells. After overnight incubation, IFN-γ by CD4 T cells was determined 
using ELISA. Statistical significance was determined using one-way ANOVA 
with Tukey posttesting (n = 7; *p < 0.05 and ****p < 0.0001).
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Platelet apoptosis and concomitant Ps 
exposure enhanced Platelet 
internalization
Storage of platelets resulted in elevated activation and apoptosis 
(Figures 3C,D). However, HLA class I expression was not signifi-
cantly affected by storage (Figure S3 in Supplementary Material), 
as opposed to mouse platelets which completely lose MHC class 
I expression after 3 days of storage (40). To investigate if platelet 
activation and/or apoptosis were involved in the increased 
internalization of stored platelets, freshly isolated platelets were 
activated or made apoptotic. Activation of platelets resulted in 
significant CD62P upregulation while annexin V binding was 
unaffected (Figure S4A in Supplementary Material). Induction 
of apoptosis in platelets resulted in >90% annexin V positive 
platelets, while CD62P expression was not affected (Figure S4B 
in Supplementary Material). Internalization of apoptotic, but 
not of activated platelets by DCs was increased compared with 
internalization of untreated platelets (Figure 4A). To investigate 
the involvement of PS in this enhanced internalization, platelets 
were incubated with purified PS, which was shown to incorporate 
into the outer membrane (33). This incubation indeed resulted 
in incorporation of PS in the outer membrane of platelets, as 
shown by increased annexin V binding, while increased annexin 
V binding was not observed after incubation with phosphatidyl-
choline (Figure S5B in Supplementary Material). Treatment with 
these phospholipids did not affect platelet activation (Figure S5B 
in Supplementary Material). Platelets incubated with PS were 
significantly more internalized compared with phosphatidylcho-
line incubated or untreated platelets (Figure 4B).
Platelet apoptosis enhanced Platelet-
specific cD4 T cell responses
Finally, the effect of the increased internalization of apoptotic 
platelets was investigated on stimulation of CD4 T cell responses 
using HPA-1a-specific CD4 T cells. While platelet-loaded DCs 
induced IFN-γ production by platelet-specific (HPA-1a) T cells 
in all conditions, IFN-γ production was significantly enhanced 
when DCs were pre-incubated with activated or apoptotic 
platelets compared with untreated platelets. DCs pre-incubated 
with apoptotic platelets, however, induced the strongest IFN-γ 
production by CD4 T cells (Figure 5).
DiscUssiOn
Platelet transfusions can elicit alloimmune responses leading to 
HLA- or HPA-specific alloantibodies, which result in rapid clear-
ance of opsonized platelets (6). Preventing or minimizing this 
alloimmunization is not only desirable to prevent refractoriness 
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to platelet transfusions, but also to diminish associated patient 
morbidity like bleeding complications (1). Currently, it is 
unknown whether alloimmunization after platelet transfusions 
is caused by residual WBCs in each blood product or whether 
platelets themselves contribute to alloimmunization (2, 6, 14, 15, 
17–19). This study demonstrates that platelets can be internalized 
by DCs and presentation of platelet-specific antigen in HLA class 
II by DCs mediates platelet-specific CD4 T cell activation. Since 
CD4 T cell help is a prerequisite for differentiation of allo-specific 
B  cells into antibody-producing plasma cells, our data strongly 
suggest that in addition to WBCs platelets are able to induce 
alloimmunization, despite contradicting suggestions in literature 
(17–20). Importantly, our data show that storage-induced apopto-
sis of platelets increased internalization and platelet-specific CD4 
T cell responses and should hence be regarded as a potential risk 
factor for alloimmunization after platelet transfusions.
Given that platelet concentrates will always contain residual 
WBCs, in animal or in vivo studies it is impossible to dissect the 
involvement of platelets and WBCs in the induction of the alloim-
mune response. Therefore, we have chosen an in vitro approach 
to study the direct involvement of platelets in the induction of 
alloimmunization. The clearest indication for the latter mecha-
nism was derived from the use of a CD4 T cell clone recognizing 
an HPA-1a peptide. Notwithstanding that HPA-1a is expressed 
by endothelial cells and trophoblasts, from the circulating cells’ 
HPA-1a expression is limited to platelets (22, 26–28, 39). As a 
result, the induced CD4 T cell activation by platelet exposed DCs 
are due to processing of platelet-derived HPA-1 and subsequent 
presentation in HLA class II, and thereby a direct indication of 
a platelet induced allo immune T  cell response. Although HLA 
class I alloimmunization after platelet transfusions is clinically 
more relevant than HPA alloimmunization (6, 7), this study used 
CD4 T  cells that respond to HPA-1a antigens to prevent that 
observed T  cell responses are induced by WBCs, which always 
contaminate isolated platelets. However, platelet-derived antigens 
are shown to be processed and presented by DCs, suggesting that 
platelet expressed HLA class I is also processed and presented after 
platelet internalization. Furthermore, via phenomena known as 
linked recognition, CD4 T cell help can be provided to B cells if 
the CD4 T cells are specific for the same antigenic complex as the 
B  cell while not necessarily recognizing the same epitope (41). 
Thus, even if processing and presentation of HLA class I peptides 
is different as HPA-1a peptides, CD4 T cells specific for HPA-1a 
peptides may also provide help to HLA-specific B cells.
Internalization, as the first step of platelet-specific alloimmuni-
zation, might well be affected by the platelets transfused. Storage of 
RBCs in this respect has been implicated as a risk factor for alloim-
munization (42, 43), and a similar effect could be considered for 
platelet products. Storage of platelets indeed significantly increased 
their internalization by DCs as compared with fresh platelets. In 
addition, Mirasol mediated pathogen reduction, an important 
new modulation of platelet products (44), further increased the 
storage-induced internalization, which may be due to enhanced 
development of storage-induced apoptosis by Mirasol pathogen 
inactivation (45, 46). Although our study only investigates Mirasol 
pathogen inactivation, Intercept or Theraflex pathogen inactivation 
also enhance storage-mediated apoptosis of platelets (44, 46–54) 
and may therefore also enhance storage-induced internalization of 
platelets. The potential enhanced risk for alloimmunization after 
pathogen reduction is contradicted by animal studies that show 
reduced or absent MHC class I allo immunization after transfusions 
with pathogen-reduced platelets (55, 56). This, however, may be 
explained by the fact that these only use fresh platelets (55, 56), while 
pathogen reduction did not affect platelet internalization directly 
after treatment, but rather enhanced the storage-mediated internali-
zation. Interestingly, two clinical trials were recently published that 
may confirm this hypothesis (57, 58). Namely, one of these studies 
stored platelets on average for 1 day and showed a protective effect 
of pathogen inactivation (58, 59), whereas the other trial stored 
platelets on average for 4 days and did not show any protective effect 
of pathogen inactivation (57).
As one of the explanations for storage enhanced internali zation, 
we demonstrated that storage-induced PS exposure enhanced inter-
nalization and eventual presentation of platelet-derived peptides to 
CD4 T cells by DCs. Priming of naïve CD4 T cells, however, is not 
only depending on peptide presentation in HLA class II, but also on 
co-stimulation and cytokine release by antigen-presenting cells. As 
a result, the final outcome of peptide presentation to naïve T cells by 
DCs is likely to be influenced by the overall inflammatory signals 
present, both by the patients’ inflammatory status and induced 
by the platelets themselves (60). Corroborating data indeed show 
the importance of the recipients’ inflammatory status during RBC 
transfusion wherein pro-inflammatory conditions will skew toward 
alloimmunization, while an anti-inflammatory environment leads 
to a more regulatory CD4 T  cell response (61, 62). Because PS 
exposure has been described to aid cell clearance via either anti- or 
pro-inflammatory pathways (63–65), the effect of the increased 
internalization and presentation of stored platelets on T cell skewing 
and alloantibody production needs investigation in clinical studies.
As this study provides strong suggestions that storage-
induced platelet apoptosis can be a risk factor for alloimmu-
nization after platelet transfusions, studies are warranted that 
investigate how platelet apoptosis during storage can be aboli-
shed or minimized. In addition, conformation by clinical studies 
is warranted because in vitro studies fail to resemble the com-
plexity of in vivo immune responses. Finally, the effect of patho-
gen inactivation on alloimmunization should be investigated 
preclinical or clinical using routine blood bank conditions, thus 
with platelet storage that resembles routine practice.
In summary, our study shows that DCs can internalize and 
present platelet-derived peptides, resulting in platelet-specific 
CD4 T cell responses. Consequently, factors such as storage of the 
platelet product, which increase internalization and presentation 
of these platelets, might increase the risk for alloimmunization, 
especially when occurring under pro-inflammatory conditions. 
While confirmation of our findings by clinical studies is war-
ranted, storage-induced apoptosis seems a risk factor for alloim-
munization after platelet transfusions.
eThics sTaTeMenT
Studies with samples from volunteer donors being described in 
this research proposal will be performed according to the Dutch 
rules and regulations with respect to the use of human materials 
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from volunteer donors. After consultation with the Medical Ethical 
Committee a system was established for obtaining blood samples 
for scientific research. This volunteer system is organized according 
to Dutch regulations and according to the Declaration of Helsinki. 
This volunteer system certifies, among others, that (1) blood 
samples used for scientific studies by researchers of the Sanquin 
Research division were drawn from healthy, anonymized volunteers 
with written informed consent; (2) no personal characteristics of 
the volunteers are registered; (3) the volunteers nor those taking 
the samples know for what project specific samples are used; and 
(4) allowed annual sample volume and frequency of donation were 
established after consultation with Sanquin Medical Secretary.
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